Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  The Lancet

• Publication date

  2007-05-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(07)60778-8PMID 17512856
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

  2007cited by this paper
• Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

  2007cited by this paper
• Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.

  2006cited by this paper
• CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).

  2006cited by this paper
• Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.

  2006cited by this paper
• Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.

  2006cited by this paper
• Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

  2005cited by this paper
• A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B].

  2005cited by this paper
• Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.

  2005cited by this paper
• Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93

  2004cited by this paper
• A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients.

  2004cited by this paper
• Goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with breast cancer. GABG trial IV-B-93.

  2004cited by this paper
• Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.

  2003cited by this paper
• Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.

  2003cited by this paper
• Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: The SOFT, TEXT, and PERCHE trials

  2003cited by this paper
• Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

  2003cited by this paper
• Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

  2002cited by this paper
• Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

  2002cited by this paper
• Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.

  2000cited by this paper
• Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.

  1991cited by this paper

• Chinese expert consensus on endocrine therapy for breast cancer (2026 edition)

  2026cites this paper
• Perspectives and Motivational Factors Surrounding Decision-Making in Women with Cancer Considering Fertility Preservation.

  2025cites this paper
• Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression.

  2025cites this paper
• SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025)

  2025cites this paper
• Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer

  2024cites this paper
• Estrogens and breast cancer

  2024cites this paper
• Lipid-Based Nanocarrier by Targeting with LHRH Peptide: A Promising Approach for Prostate Cancer Radio-Imaging and Therapy.

  2024cites this paper
• Evaluation of patients' care pathway before the first consultation in the radiotherapy department of Centre Hospitalier Nganda (Kinshasa) for breast cancer treatment

  2024cites this paper
• Herbal nanogels: Revolutionizing skin cancer therapy through nanotechnology and natural remedies

  2023cites this paper
• Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey

  2023cites this paper
• Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers

  2023cites this paper
• Combined Therapy with Anthracyclines and GnRH Analogues for Breast Cancer: Impact on Ischemic Heart Disease

  2023influential citation
• AMPAR receptor inhibitors suppress proliferation of human small cell lung cancer cell lines

  2023cites this paper
• The roles of anti-Müllerian hormone in breast cancer

  2023cites this paper
• SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

  2023cites this paper
• The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer

  2023cites this paper
• A method to detect fulvestrant interference in estradiol in breast cancer patients

  2023cites this paper
• Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use.

  2023cites this paper
• Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects

  2023cites this paper
• Immunohistochemical Profiling of HER-2/neu, Steroid Hormone Receptors and KI-67 Biomarkers in A Cohort of Nigerian Women with Breast Cancer

  2023cites this paper
• The beneficial effects of tamoxifen on arteries: a key player for cardiovascular health of breast cancer patient.

  2023cites this paper
• Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer

  2022cites this paper
• Polypharmacy and medication fill nonadherence in a population-based sample of adolescent and young adult cancer survivors, 2008–2017

  2022cites this paper
• In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.

  2022cites this paper
• The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation

  2022cites this paper
• Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

  2022cites this paper
• GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation

  2022cites this paper
• Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer

  2021cites this paper
• Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer

  2021influential citation
• Revisiting Adjuvant Hormone Therapy in Premenopausal Women With Breast Cancer: Escalation and De-Escalation.

  2021cites this paper
• Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use

  2021cites this paper
• Adherence to endocrine therapy including ovarian suppression: A large observational cohort study of US women with early breast cancer

  2021cites this paper
• Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy

  2021cites this paper
• Neoadjuvant endocrine therapy in women with operable breast cancer: A retrospective analysis of real-world use.

  2021cites this paper
• Awareness of the Causes Leading to Surgical Ablation of Ovarian Function in Premenopausal Breast Cancer—A Single-Center Analysis

  2021cites this paper
• Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea

  2021cites this paper
• Cyclophosphamide-Free Adjuvant Chemotherapy for Ovarian Protection in Young Women With Breast Cancer: A Randomized Phase 3 Trial

  2021cites this paper
• Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue

  2021cites this paper
• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

  2021cites this paper
• Measuring Ovarian Escape in Premenopausal Estrogen Receptor Positive Breast Cancer Patients on Ovarian Suppression Therapy.

  2021cites this paper
• The methodological quality of individual participant data meta-analysis on intervention effects: systematic review

  2021cites this paper
• Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review.

  2021cites this paper
• A new look at old problems: Ovarian function suppression in the real world

  2021cites this paper
• Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women

  2021cites this paper
• Management of hormone receptor-positive, HER2-negative early breast cancer.

  2020cites this paper
• SPECIAL SERIES: ONCOLOGY CLINICAL TRIALS IN AFRICA: THE LANDSCAPE AND UPDATES

  2020cites this paper
• Extended endocrine therapy in premenopausal breast cancer patients: Where are we now?

  2020cites this paper
• Studies of side effects related to adjuvant breast cancer regimens with focus on chemotherapy

  2020cites this paper
• Controversies Regarding Ovarian Suppression and Infertility in Early Stage Breast Cancer

  2020cites this paper
• Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers

  2020cites this paper
• CMAR_A_231524 813..817

  2020cites this paper
• Surgical oophorectomy or GnRH plus tamoxifen adjuvant therapy for breast cancer in low-risk premenopausal women: comparative benefits and risks

  2020cites this paper
• LHRH‐Targeted Redox‐Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple‐Negative Breast Cancer

  2020cites this paper
• Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.

  2020cites this paper
• Altered prolactin and androgen receptors expression in companion rat benign mammary tumors.

  2020cites this paper
• Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.

  2020cites this paper
• Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.

  2020cites this paper
• Cancer of the Breast

  2020cites this paper
• Protective effect of gonadotropin-releasing hormone agonist against chemotherapy-induced ovarian dysfunction: A meta-analysis

  2019cites this paper
• Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer

  2019cites this paper
• Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019

  2019cites this paper
• Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer

  2019cites this paper
• [LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?]

  2019cites this paper
• Evaluation of deslorelin implant on subsequent mammary tumors of rats (Rattus norvegicus)

  2019cites this paper
• Adjuvant Systemic Therapy in Breast Cancer

  2019cites this paper
• Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy

  2019cites this paper
• Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs

  2019cites this paper
• Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.

  2019cites this paper
• Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure

  2019cites this paper
• Adjuvant Systemic Therapy: Endocrine Therapy

  2019cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant)

  2018cites this paper
• Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study

  2018cites this paper
• Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

  2018cites this paper
• Adjuvante endokrine Therapie beim frühen Mammakarzinom

  2018cites this paper
• Importance of evaluation of ovarian function in women with breast cancer when using endocrinotherapy

  2018cites this paper
• Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer

  2018cites this paper
• Adjuvant and neoadjuvant systemic therapies for early-stage breast cancer

  2018cites this paper
• An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

  2018cites this paper
• Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer

  2018cites this paper
• Adjuvant Endocrine Therapy

  2018cites this paper
• Diretrizes diagnósticas e terapêuticas do carcinoma de mama

  2018cites this paper
• THE ROLE OF OVARIAN SUPPRESSION IN THE TREATMENT OF EARLY-STAGE HORMONE-SENSITIVE BREAST CANCER

  2018cites this paper
• Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Breast Cancer in Special Groups: Young Women with Early Breast Cancer

  2018cites this paper
• Maligne Tumoren der Mamma

  2018cites this paper
• SEOM clinical guidelines in early stage breast cancer (2018)

  2018cites this paper
• Challenges in Treating Estrogen Receptor-Positive Breast Cancer

  2018cites this paper
• Adjuvant Endocrine Therapy for Breast Cancer

  2018cites this paper
• Adjuvant Endocrine Therapy

  2018cites this paper
• Hormone Therapy in Breast Cancer: Where do We Stand?

  2017cites this paper
• The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer

  2017cites this paper
• Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women

  2017cites this paper
• General Overview and Treatment Recommendations for Young Women with Breast Cancer.

  2017cites this paper
• Endokrine antihormonelle Therapie in der Prämenopause

  2017cites this paper
• Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment

  2017cites this paper
• Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

  2017cites this paper
• How Young Is Too Young in Breast Cancer?—Young Breast Cancer Is Not a Unique Biological Subtype

  2017cites this paper
• Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment

  2017cites this paper